Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Hunan Province Tumor Hospital70 enrolled

Overview

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Main enrolled criteria: Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * HER 2 Insertion or Amplification * First Diagnosis and Treatment * Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody Exclusion Criteria: * Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women

Locations (1)

Yongchang Zhang

Changsha, Hunan, China

RECRUITING

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: may 2020- may 2021 (1 year)

Secondary Outcomes

Overall survival

Time frame: may 2020- may 2021 (1 year)

ORR

To measure the patients's overall response rate

Time frame: may 2020- may 2021 (1 year)

Central Contacts

Yongchang Zhang, MD

CONTACT

+8613873123436 zhangyongchang@csu.edu.cn

Nong Yang, MD

CONTACT

+8613055193557 yangnong0217@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.